TMG Partners Sign Clovis Oncology to 10-Year Lease for 32,000 SQFT at 133O Broadway in Oakland

TMG Partners, Bay Area, Clovis Oncology, Oakland, Mission Bay, San Francisco, Arup, Oracle, BART, Cushman & Wakefield, JLL
Photo courtesy: TMG Partners

OAKLAND, Calif. (November 27, 2017) – TMG Partners, one of the Bay Area’s largest mixed-use property developers, announced today that biopharmaceutical company Clovis Oncology (NASDAQ: CLVS), an innovator in cancer drugs, signed a ten-year lease for 32,000 square feet at the developer’s 1330 Broadway property in Downtown Oakland. Clovis is expanding its footprint from Mission Bay in San Francisco to include its new Oakland office and will occupy the building’s 9th and 10th floors.

With the addition of Clovis Oncology, 1330 Broadway, an 18-story, 316,000-square-foot office building is now 85 percent leased. Clovis will be joining other recent new tenants including Oracle, which recently took occupancy of 16,000 square feet on the 17th floor, and Arup, who signed a ten-year lease for 16,000 square feet on the 13th floor, in moving to the newly renovated office tower.

TMG Partners, Bay Area, Clovis Oncology, Oakland, Mission Bay, San Francisco, Arup, Oracle, BART, Cushman & Wakefield, JLL
Photo courtesy: TMG Partners
“TMG Partners’ 1330 Broadway project has proven very attractive to innovative and creative companies who are looking to locate in fully renovated, modern spaces within architecturally significant buildings in Oakland,” said David Cropper, TMG’s Director of Development. “The mid-century modern design building, with 13’+ ceiling heights and large curtain wall windows allows for an open office plan that is very much in demand by today’s tenants,” Cropper added.

“We continue to receive positive feedback from current and prospective tenants about the new lobby, common areas and the rest of the building improvements,” said Adam Chall, Partner at TMG. “The 1330 Broadway project also enjoys immediate access to BART and all of the amenities in Downtown and Uptown Oakland,” Chall added.

TMG’s renovations to the project include a new main lobby and building entrance, new common area finishes, major elevator and building systems’ modernization, refurbished conference facilities, enhanced bike parking, and commuter showers. The building is at the 12th Street Oakland BART station and is directly served by AC Transit. 1330 Broadway is TMG’s first Oakland redevelopment. Last year, the firm also acquired 2201 Broadway, an eight-story 198,000-square-foot office building in Uptown Oakland.

“We are very excited to be moving into 1330 Broadway. Finding a location close to BART for our employees was an important factor in our decision. Everyone really appreciates the high ceilings and great views from the building,” said Daniel Muehl, Clovis Oncology’s Senior VP Finance.

TMG Partners was represented in this transaction by John Dolby and Dane Hooks of Cushman & Wakefield, and Clovis was represented by Gregg Walker and Grant Yeatman of JLL.

About TMG Partners
TMG Partners, founded in 1984 and headquartered in San Francisco, is a full-service real estate development and management company. TMG has developed more than 27.5 million square feet of property in more than twenty cities across the Bay Area counties of Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara. One of the most active developers in the region, TMG has developed a variety of office, retail, residential and industrial properties, ranging from office campus and multi-story properties in urban, infill locations to mixed-use retail and single-story suburban buildings. For detailed information, visit www.tmgpartners.com.

About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK. Please visit www.clovisoncology.com for more information.